Inhibition of human hepatic CYP isoforms by mGluR5 antagonists

Life Sciences

Volumn 75, Issue 8, 2004, Pages 947-953

  Green, Mitchell D ^a   Jiang, Xiaohui ^a   King, Christopher D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CYP1A2 inhibition; Cytochrome P450; Metabotropic glutamate receptors

Indexed keywords

2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; THIAZOLES;

EID: 2942525894     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2004.02.009     Document Type: Article

References (18)

1. 3H]3-methoxy-5-(pyridin-2- ylethynyl)pyridine. European Journal of Pharmacology. 473:2003;35-40
2. Bradbury M.J., Giracello D.R., Chapamn D.F., Holtz G., Schaffhauser H., Rao S.P., Varney M.A., Anderson J.J. Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: Interaction with serotonergic systems. Neuropharmacology. 44:2003;562-572
3. Christensen M., Tybring G., Mihara K., Yasui-Furokori N., Carrillo J.A., Ramos S.I., Andersson K., Dahl M.L., Bertilsson L. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P450A2) and omeprazole (cytochrome 2C19). Clinical Pharmacology and Therapeutics. 71:2002;141-152
4. Cosford N.D.P., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., Varney M.A. 3-[(2-Methyl-1, 3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. Journal of Medicinal Chemistry. 46:2003;204-206
5. Delaporte E., Rodrigues D.A. Cytochrome P450 Assays. Enna S.J. Current Protocols in Pharmacology. 2003;John Wiley and Sons, New York. Chapter 3, Unit 3.9
6. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 38:1999;1493-1503
7. Hiemke C., Peled A., Jabarin M., Hadjez J., Weigmann H., Hartter S., Modai I., Ritsner M., Silver H. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. Journal of Clinical Psychopharmacology. 22:2002;502-506
8. Lee S.S.T., Buters J.T.M., Pineau T., Renandez-Salguero P., Gonzalez F.J. Role of CYP2E1 in the hepatotoxicity of acetaminophen. Journal of Biological Chemistry. 271:1996;12063-12067
9. Mathiesen J.M., Svensen N., Brauner-Osborne H., Thomsen C., Ramirez M.T. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. British Journal of Pharmacology. 138:2003;1026-1030
10. Murray G.I., William T.M., Greenlee W.F., Burke M.D. Regulation, function and tissue-specific expression of cytochrome P450 CYP1B1. Annual Review of Pharmacology and Toxicology. 41:2001;297-316
11. Obach R.S., Reed-Hagen A.E. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metabolism and Disposition. 30:2002;831-837
12. Pin J.P., Duvoinsin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 34:1995;1-26
13. Racha J.K., Rettie A.E., Kunz K.L. Mechanism-based inactivation of human cytochrome P4501A2 by furafylline; detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry. 37:1998;7407-7419
14. Sinclair J.F., Szakacs J.G., Wood S.G., Walton H.S., Bement J.L., Gonzalez F.J., Jeffery E.H., Wrighton S.A., Bement W.J., Sinclair P.R. Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice. Toxicology and Applied Pharmacology. 168:2000;114-122
15. Storto M., Ngomba R.T., Battaglia G., Freitas I., Griffini P., Richelmi P., Nicoletti F., Vairetti M. Selective blockade of mGluR5 metabotropic glutamate receptors is protective against acetaminophen hepatotoxicity in mice. Journal of Hepatology. 38:2003;179-187
16. Tarrus E., Cami J., Roberts D.J., Spickett R.G., Celdran E., Segura J. Accumulation of caffeine in healthy volunteers treated with furafylline. British Journal of Clinical Pharmacology. 23:1987;9-18
17. Varney M.A., Cosford N.D.P., Jachec C., Rao S.P., Sacaan A., Lin F.-F., Bleicher L., Santori E.M., Flor P.J., Allgeier H., Gasparini F., Kuhn R., Hess S.D., Velicelebi G., Johnson E.C. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic gluatamate receptor type 5. Journal of Pharmacology and Experimental Therapeutics. 290:1999;170-181
18. Yao C., Kunze K.L., Kharasch E.D., Wang Y., Trager W.F., Ragueneau I., Levy R.H. Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P450 1A2. Clinical Pharmacology and Therapeutics. 70:2001;415-424